There are currently 130 active clinical trials seeking participants for Major Depressive Disorder research studies. The states with the highest number of trials for Major Depressive Disorder participants are California, Florida, Texas and New York.
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
NCT06529029
Recruiting
This protocol proposes an initial randomized clinical trial that includes all patients with suicidal ideation (SI) at baseline, and with SI as the primary outcome measure to examine whether Right Unilateral Low-Amplitude Pulse - Seizure Therapy (RUL LAP-ST) treatment has more magnitude and rate of remission of SI as conventional pulse amplitude Right Unilateral Electroconvulsive Therapy (RUL ECT) (based on our prior secondary analysis). Our central hypothesis is that RUL LAP-ST has significantly... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/30/2024
Locations: Pine Rest Christian Mental Health Services, Grand Rapids, Michigan
Conditions: Suicidal Ideation, Major Depressive Disorder, Schizo Affective Disorder, Bipolar Disorder
Register for Updates
Decoding and Modulating Affective Brain States
NCT05437705
Recruiting
Generating personalized brain signatures of negative emotion along with personalized brain stimulation protocols to disrupt these patterns. We plan to use fMRI and muscle activity data to determine negative affect maps for each participant. We will then try a variety of patterned repetitive transcranial magnetic stimulation sequences while recording fMRI which will be the basis of two sessions of 3-day individualized brain stimulation designed to reduce negative affect.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/19/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Rumination, Major Depressive Disorder, Anxiety
Register for Updates
Study of ALTO-300 in MDD
NCT05922878
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/05/2024
Locations: Site 200, Phoenix, Arizona +43 locations
Conditions: Major Depressive Disorder
Register for Updates
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
NCT05327699
Recruiting
The main purpose of this study is to investigate the effects of ketamine on decision-making and emotion processing in a sample of individuals diagnosed with Major Depressive Disorder (MDD).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/01/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Major Depressive Disorder
Register for Updates
Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses
NCT04276259
Recruiting
The central goal of this application is to demonstrate the causal contribution of reward learning signals (expected values and reward prediction errors \[RPE\]) to antidepressant responses (Aim1) by experimentally manipulating expected values using transcranial magnetic stimulation (TMS) targeting the vmPFC (Aim 2) and μ-opioid striatal RPE signal using pharmacological approaches (Aim 3).
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
07/01/2024
Locations: Bellefield Tower, Pittsburgh, Pennsylvania
Conditions: Major Depressive Disorder, Depression
Register for Updates
5-HTP and Creatine for Depression R33 Phase
NCT05895747
Recruiting
This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP 100mg BID + creatine 5g daily, 5-HTP 200mg BID + creatine 10g daily, vs double placebo, for 8 weeks. The ability of the interventions to affect biomarkers associated with depression will be assessed using brain phosphorus magnetic resonance spectroscopy, functional connectivity imaging, and plasma... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/01/2024
Locations: University of Utah Department of Psychiatry, Salt Lake City, Utah
Conditions: Major Depressive Disorder
Register for Updates
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
NCT06480201
Recruiting
The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (GBP) in the context of a single infusion. Our study design captures the clinical variation associated with real-world treatment resistant depression (TRD) patients and allows us to analyze the relativ... Read More
Gender:
ALL
Ages:
Between 21 years and 45 years
Trial Updated:
06/24/2024
Locations: Wells Medicine, Houston, Texas +1 locations
Conditions: Healthy, Major Depressive Disorder, Treatment Resistant Depression
Register for Updates
Mindfulness Engaged Neurostimulation for Depression
NCT06399406
Recruiting
Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of ~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/20/2024
Locations: University of California San Diego, La Jolla, California
Conditions: Depression, Treatment Resistant Depression, Major Depressive Disorder, Depressive Disorder
Register for Updates
Predicting SSRI Efficacy in Veterans With PTSD
NCT04183205
Recruiting
This is a research study to examine the effectiveness of a brief screening method that may predict which people with posttraumatic stress disorder (PTSD) or depression are most likely to show a positive response to selective serotonin reuptake inhibitor (SSRI) medications. Participants will be recruited over approximately 5.25 years, until at least 94 participants complete the 17 week study.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/17/2024
Locations: VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts +1 locations
Conditions: Posttraumatic Stress Disorder, Major Depressive Disorder
Register for Updates
Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
NCT05570812
Recruiting
This study will determine the effects of pregnenolone on brain function, inflammation and depressive symptoms in people with HIV who have depression. Participants in this study will receive a pill of either pregnenolone or placebo, and can stay on their current antidepression medications. Brain imaging and behavioral assessments will be performed during the study.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/07/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Major Depressive Disorder, Anxiety Depression, Hiv
Register for Updates
Mindful Self-Compassion for Anxiety Disorders and Depression
NCT05671419
Recruiting
The study will compare 8-week Mindful Self-Compassion training, compared to a control group that does not receive the intervention, on anxiety and depression symptom severity in patients with diagnosed anxiety disorders (generalized anxiety disorder, social anxiety disorder, and panic disorder) or major depressive disorder.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/06/2024
Locations: Georgetown University Medical Center, Washington, District of Columbia
Conditions: Anxiety Disorders, Generalized Anxiety Disorder, Social Anxiety Disorder, Social Phobia, Panic Disorder, Agoraphobia, Major Depressive Disorder
Register for Updates
Network Neurofeedback Using 7-Tesla MRI to Reduce Rumination Levels in Depression
NCT05933148
Recruiting
Patients with major depressive disorder (MDD) exhibit increased levels of rumination (i.e. repetitive thinking and focus on negative mood states) which have been found to increase the risk of depressive relapse. The ability to reduce rumination levels among these patients is greatly needed. Rumination is known to be associated with the default mode network (DMN) region activity. Implementing the Dependency Network Analysis (DEPNA), a recently developed method by the research team to quantify the... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/05/2024
Locations: Icahn School Of Medicine at Mount Sinai, New York, New York
Conditions: Major Depressive Disorder
Register for Updates